Mall, Marcus A.

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Middleton, P. G., Mall, M. A., Dřevínek, P., Lands, L. C., McKone, E. F., Polineni, D., Ramsey, B. W., Taylor-Cousar, J. L., Tullis, E., Vermeulen, F., et al. (2019) · New England Journal of Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 2,198

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Heijerman, H. G. M., McKone, E. F., Downey, D. G., Van Braeckel, E., Rowe, S. M., Tullis, E., Mall, M. A., Welter, J. J., Ramsey, B. W., McKee, C. M., et al. (2019) · The Lancet

Cystic Fibrosis Research AdvancesPharmacogenetics and Drug Metabolism

Cited by 1,414

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., et al. (2020) · Nature

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 1,310

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

Keating, D., Marigowda, G., Burr, L., Daines, C., Mall, M. A., McKone, E. F., Ramsey, B. W., Rowe, S. M., Sass, L. A., Tullis, E., et al. (2018) · New England Journal of Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 726

Electrolyte transport in the mammalian colon: mechanisms and implications for disease

Kunzelmann, K., & Mall, M. (2002) · Physiological Reviews

Ion Transport and Channel RegulationCystic Fibrosis Research Advances

Cited by 655

VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

Davies, J. C., Moskowitz, S. M., Brown, C., Horsley, A., Mall, M. A., McKone, E. F., Plant, B. J., Prais, D., Ramsey, B. W., Taylor-Cousar, J. L., et al. (2018) · New England Journal of Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 331

CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank

Geurts, M. H., de Poel, E., Amatngalim, G. D., Oka, R., Meijers, F. M., Kruisselbrink, E., van Mourik, P., Berkers, G., de Winter-de Groot, K. M., Michel, S., et al. (2020) · Cell Stem Cell

CRISPR and Genetic EngineeringCystic Fibrosis Research Advances

Cited by 222

Complement activation induces excessive T cell cytotoxicity in severe COVID-19

Georg, P., Astaburuaga-García, R., Bonaguro, L., Brumhard, S., Michalick, L., Lippert, L. J., Kostevc, T., Gäbel, C., Schneider, M., Streitz, M., et al. (2022) · Cell

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 218

Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial

Griese, M., Costa, S., Linnemann, R. W., Mall, M. A., McKone, E. F., Polineni, D., Quon, B. S., Ringshausen, F. C., Taylor-Cousar, J. L., Withers, N. J., et al. (2021) · American Journal of Respiratory and Critical Care Medicine

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 163

Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles

Taylor-Cousar, J. L., Mall, M. A., Ramsey, B. W., McKone, E. F., Tullis, E., Marigowda, G., McKee, C. M., Waltz, D., Moskowitz, S. M., Savage, J., et al. (2019) · ERJ Open Research

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 105

Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study

Daines, C. L., Tullis, E., Costa, S., Linnemann, R. W., Mall, M. A., McKone, E. F., Polineni, D., Quon, B. S., Ringshausen, F. C., Rowe, S. M., et al. (2023) · European Respiratory Journal

Cystic Fibrosis Research AdvancesPharmacogenetics and Drug Metabolism

Cited by 100

Cellular uptake and localization of inhaled gold nanoparticles in lungs of mice with chronic obstructive pulmonary disease

Geiser, M., Quaile, O., Wenk, A., Wigge, C., Eigeldinger-Berthou, S., Hirn, S., Schäffler, M., Schleh, C., Möller, W., Mall, M. A., et al. (2013) · Particle and Fibre Toxicology

Inhalation and Respiratory Drug DeliveryNanoparticle-Based Drug Delivery

Cited by 97

Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: A multicentre, open-label, randomised trial

Ballmann, M., Hubert, D., Assael, B. M., Staab, D., Hebestreit, A., Naehrlich, L., Nickolay, T., Prinz, N., Holl, R. W., Staden, U., et al. (2018) · The Lancet Diabetes & Endocrinology

Cystic Fibrosis Research AdvancesDiabetes Treatment and Management

Cited by 71

A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF

Thee, S., Stahl, M., Fischer, R., Sutharsan, S., Ballmann, M., Müller, A., Lorenz, D., Urbanski-Rini, D., Püschner, F., Amelung, V. E., et al. (2021) · BMC Pulmonary Medicine

Cystic Fibrosis Research AdvancesTelemedicine and Telehealth Implementation

Cited by 25